Department of Radiotherapy and Oncology, Government Medical College and Cancer Hospital, Aurangabad, Maharashtra, India.
J Cancer Res Ther. 2023 Jan 1;19(Suppl 2):S530-S535. doi: 10.4103/jcrt.jcrt_934_22. Epub 2022 Dec 16.
Head and neck cancers are treated by multimodality methods like surgery, radiotherapy, and chemotherapy. Hypothyroidism is one of the late side effects of radiation to the neck. The main aim of the study was to assess the incidence of primary hypothyroidism in patients with head and neck cancers, who received therapeutic external beam radiation; to evaluate the time duration and the total dose of radiation for the development of hypothyroidism.
A prospective observational study was conducted in our institute on 200 patients from December 2018 to April 2020 with head and neck cancers, which were proven histopathologically. They received external beam radiation using Cobalt 60 or Linear accelerator. A thyroid function test was done in patients after 3 months and 6 months of completion of radiotherapy.
The incidence of hypothyroidism was 8% after 3 months (P value = 0.0088) post radiation and increased to 14% after 6 months (P value = 0.0024). Of the patients who developed hypothyroidism, a maximum number of cases (24; 86%) were given 60 Gy radiation dose, three (10%) were given 40-59 Gy, and one (3%) was given up to 40 Gy as the mean dose of radiation to the lower neck. A P value of 0.750 was not significant; hence, a dose of radiation was not a significant factor. The patients treated with the two-dimensional (2-D) technique (50%) had a higher incidence of hypothyroidism than the patients treated with three-dimensional conformal radiation therapy (3D-CRT) (14.8%) and intensity-modulated radiation therapy (IMRT) (9%). The use of concurrent cisplatin was not a significant factor for hypothyroidism (P value = 1).
Thyroid function test should be done in patients who received therapeutic external beam radiation to the neck at baseline and periodically. The early detection and treatment can prevent complications of long-term thyroid hypofunction like hypercholesterolemia, cardiovascular side effects, menstrual irregularities, infertility, peripheral neuropathy, depression, and myxoedema.
头颈部癌症采用手术、放疗和化疗等多模态方法治疗。甲状腺功能减退症是颈部放疗的晚期副作用之一。本研究的主要目的是评估接受颈部治疗性外照射的头颈部癌症患者原发性甲状腺功能减退症的发生率;评估甲状腺功能减退症发生的时间和总剂量。
本研究为前瞻性观察性研究,于 2018 年 12 月至 2020 年 4 月在我院进行,纳入经组织病理学证实的头颈部癌症患者 200 例。采用钴 60 或直线加速器进行外照射。放疗结束后 3 个月和 6 个月时,对患者进行甲状腺功能检查。
放疗后 3 个月(P 值=0.0088)时甲状腺功能减退症的发生率为 8%,6 个月时增至 14%(P 值=0.0024)。发生甲状腺功能减退症的患者中,最多(24 例,86%)接受 60 Gy 剂量照射,3 例(10%)接受 40-59 Gy 剂量照射,1 例(3%)接受的剂量低于 40 Gy,即下颈区平均照射剂量。P 值为 0.750,无统计学意义,故照射剂量不是显著因素。二维(2-D)技术治疗的患者(50%)发生甲状腺功能减退症的发生率高于三维适形放疗(3D-CRT)(14.8%)和调强放疗(IMRT)(9%)的患者。顺铂同期应用不是甲状腺功能减退症的显著因素(P 值=1)。
应在基线和定期时对接受颈部治疗性外照射的患者进行甲状腺功能检查。早期发现和治疗可预防长期甲状腺功能低下引起的胆固醇升高、心血管副作用、月经不规律、不孕、周围神经病、抑郁和黏液性水肿等并发症。